Acute-Phase Serum Amyloid A Regulates Tumor Necrosis Factor alpha and Matrix Turnover and Predicts Disease Progression in Patients With Inflammatory Arthritis Before and After Biologic Therapy

St. Vincent's University Hospital, Dublin Academic Medical Centre, The Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland.
Arthritis & Rheumatology (Impact Factor: 7.87). 04/2012; 64(4):1035-45. DOI: 10.1002/art.33455
Source: PubMed

ABSTRACT In this study, we demonstrated a specific relationship between A-SAA and clinical disease activity in inflammatory arthritis, as measured by the SJC. Hepatic induction of acute-phase proteins including CRP is a nonspecific feature of systemic inflammation in response to diverse causes, including trauma, infection, and autoimmune disease (36). In contrast to other hepatic-derived acute-phase proteins, A-SAA at concentrations of up to 1,000 μg/ml has previously been reported in RASFs, which may exceed serum levels obtained in the same subjects (37). Measurement of serum A-SAA levels, which may be partly SF-derived, may therefore be a more accurate indicator of radiographic progression in clinical practice, although further direct comparison with high-sensitivity CRP may be useful. Although heterogeneous by diagnosis, the patients with RA and the patients with PsA in this cohort were indistinguishable in terms of disease duration and baseline radiographic damage prior to biologic therapy. The relatively high incidence of radiographic progression observed in both patients with RA and patients with PsA prior to biologic therapy is likely to be due to a combination of factors, including the high incidence of baseline structural damage, the long history of DMARD-resistant disease, incomplete adherence to therapy, and a relatively high rate of biologic monotherapy, which has been shown to be associated with worse radiographic outcomes (38).


Available from: Robin Poole, Sep 23, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rupture of abdominal aortic aneurysm (AAA), a major cause of death in the aged population, is characterized by vascular inflammation and matrix degradation. Serum amyloid A (SAA), an acute-phase reactant linked to inflammation and matrix metalloproteinase induction, correlates with aortic dimensions before aneurysm formation in humans. We investigated whether SAA deficiency in mice affects AAA formation during angiotensin II (Ang II) infusion. Plasma SAA increased ≈60-fold in apoE(-/-) mice 24 hours after intraperitoneal intraperitoneal Ang II injection (100 μg/kg; n=4) and ≈15-fold after chronic 28-day Ang II infusion (1000 ng/kg per minute; n=9). AAA incidence and severity after 28-day Ang II infusion was significantly reduced in apoE(-/-) mice lacking both acute-phase SAA isoforms (SAAKO; n=20) compared with apoE(-/-) mice (SAAWT; n=20) as assessed by in vivo ultrasound and ex vivo morphometric analyses, despite a significant increase in systolic blood pressure in SAAKO mice compared with SAAWT mice after Ang II infusion. Atherosclerotic lesion area of the aortic arch was similar in SAAKO and SAAWT mice after 28-day Ang II infusion. Immunostaining detected SAA in AAA tissues of Ang II-infused SAAWT mice that colocalized with macrophages, elastin breaks, and enhanced matrix metalloproteinase activity. Matrix metalloproteinase-2 activity was significantly lower in aortas of SAAKO mice compared with SAAWT mice after 10-day Ang II infusion. Lack of endogenous acute-phase SAA protects against experimental AAA through a mechanism that may involve reduced matrix metalloproteinase-2 activity. © 2015 American Heart Association, Inc.
    Arteriosclerosis Thrombosis and Vascular Biology 03/2015; 35(5). DOI:10.1161/ATVBAHA.114.304776 · 5.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Tumor necrosis factor-alpha (TNF-α) inhibitor has been implicated to have an effect on periodontal condition in patients with rheumatoid arthritis (RA). The aim of the present study is to assess the effect of a fully humanized anti-TNF-α monoclonal antibody adalimumab (ADA) on periodontal condition in patients with RA, and to compare serum protein profiles before and after ADA therapy. Methods: The study participants consisted of 20 patients with RA treated with ADA. Clinical periodontal and rheumatologic parameters and serum cytokine levels were evaluated at baseline and 3 months later. Serum protein spot volume was examined with two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis. Proteins with significant difference in abundance before and after ADA therapy were determined, and identified with mass spectrometry and protein databases. Results: The patients showed a significant decrease in gingival index (P = 0.002), bleeding on probing (P = 0.003), probing depth (P = 0.002), disease activity score including 28 joints using C-reactive protein (P = 0.0004), and serum levels of TNF-α (P = 0.0003) and interleukin-6 (P < 0.0001) after ADA medication, although plaque levels were comparable. Among a total of 495 protein spots obtained, nine spots were significantly decreased in abundance at reassessment, which corresponds to complement factor H, phospholipase D, serum amyloid A, complement component 4, and alpha-1-acid glycoprotein (P < 0.01). Conclusions: These results suggest an beneficial effect of ADA therapy on periodontal condition in patients with RA, which might be related to differences in serum protein profiles before and after ADA therapy.
    Journal of Periodontology 05/2014; 85(11):1-12. DOI:10.1902/jop.2014.140194 · 2.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. Rheumatoid arthritis (RA) is a systemic, inflammatory disease. Serum amyloid A (SAA) is an acute-phase protein, involved in pathogenesis of atherosclerosis. The aim of the study was to assess serum concentration of SAA in RA patients, with reference to other inflammatory parameters and markers of extra-articular involvement. Methods. The study population consisted of 140 RA patients, low/moderate disease activity (L/MDA) in 98 (70%) patients and high disease activity (HDA) in 42 (30%). Comprehensive clinical and laboratory assessment was performed with evaluation of electrocardiogram and carotid intima-media thickness. Results. The mean SAA concentration [327.0 (263.4) mg/L] was increased highly above the normal value, even in patients with L/MDA. Simultaneously, SAA was significantly higher in patients with HDA versus L/MDA. The mean SAA concentration was significantly higher in patients treated with glucocorticoids, was inversely associated with QTc duration, and was markedly higher in patients with atherosclerotic plaques, emphasizing increased CV risk. SAA was significantly higher in patients with increased cystatin-C level. Conclusions. In RA patients, high serum SAA concentration was strongly associated with activity of the disease and risk of CV and renal involvement. Recurrent assessment of SAA may facilitate searching patients with persistent inflammation and risk of extra-articular complications.
    Mediators of Inflammation 11/2014; 2014:793628. DOI:10.1155/2014/793628 · 2.42 Impact Factor